Atlas FDA

ADVIA Centaur anti-HBs2 (aHBs2), Atellica IM aHBs2

FDA premarket approval P100039/S014 · decided 2022-02-16

Approval details

PMA number
P100039
Supplement
S014
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
ADVIA Centaur anti-HBs2 (aHBs2), Atellica IM aHBs2
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
Siemens Healthcare Diagnostics, Inc.
Date received
2022-01-20
Decision date
2022-02-16
Days to decision
27 days
Decision code
OK30
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Tarrytown, NY
Statement
Manufacturing process change for kit components.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Atellica CH Acetaminophen 2 (ACTM) (K261364)Siemens Healthcare Diagnostics, Inc.2026-07-24
Atellica CH Diazo Total Bilirubin (D_TBil) (K251998)Siemens Healthcare Diagnostics, Inc.2026-02-27
Atellica® IM TSH3-Ultra II (TSH3ULII) (K251543)Siemens Healthcare Diagnostics, Inc.2026-02-06
Atellica IM Total PSA II (tPSAII) (K251630)Siemens Healthcare Diagnostics, Inc.2026-01-05
ADVIA Centaur Anti-Thyroglobulin II (aTgII) (K250816)Siemens Healthcare Diagnostics, Inc.2025-12-04
ADVIA Centaur Anti-Thyroid Peroxidase II (K250250)Siemens Healthcare Diagnostics, Inc.2025-10-17
Atellica IM Thyroglobulin (Tg) (K242981)Siemens Healthcare Diagnostics, Inc.2025-06-20
Atellica® CH Creatinine_3 (Crea3) (K242685)Siemens Healthcare Diagnostics, Inc.2024-12-04